BCAX
Bicara Therapeutics Inc.
$22.58
-2.21%
2026-05-08
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Key Fundamentals
P/E Ratio
3.26
Forward P/E
-7.64
EPS (TTM)
$-2.52
ROE
-30.9%
Profit Margin
0.0%
Debt/Equity
0.43
Price/Book
3.15
Market Cap
$1.52B
Avg Volume (10D)
350K
Recent Breakout Signals
No recent breakout signals detected for BCAX.
Recent Price Range (60 Days)
60D High
$24.25
60D Low
$13.75
Avg Volume
527K
Latest Close
$22.58
Get breakout alerts for BCAX
Sign up for Breakout Scanner to receive daily notifications when BCAX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Bicara Therapeutics Inc. (BCAX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors BCAX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. BCAX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.